Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Bevacizumab + trastuzumab is a combination of two monoclonal antibodies used primarily in the treatment of HER2-positive metastatic breast cancer. Bevacizumab targets and inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, which is essential for tumor growth and metastasis. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2), inhibiting proliferation of tumor cells that overexpress this receptor. The combination has been studied in several clinical trials, often with chemotherapy agents such as docetaxel or capecitabine, showing improved progression-free survival but not always overall survival benefit compared to standard regimens. Both drugs are biologics developed for targeted cancer therapy[1][4][5].
- Other names
- bevacizumab + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + trastuzumab.